Computer-aided detection (CAD) developer Medicsight has filed a 510(k) application to the U.S Food and Drug Administration (FDA) for its ColonCAD image analysis software.
The London-based firm previously received regulatory approval to market ColonCAD in Europe, Canada, Australia, China, and Brazil.
Related Reading
Road to RSNA, CAD, Medicsight, October 30, 2008
Medicsight touts ESGAR colon CAD data, June 19, 2008
Medicsight parent trims net loss, March 18, 2008
Medicsight, Toshiba ink deal, February 14, 2008
Medicsight, Visage Imaging to collaborate, November 25, 2007
Copyright © 2008 AuntMinnie.com
![Images show the pectoralis muscles of a healthy male individual who never smoked (age, 66 years; height, 178 cm; body mass index [BMI, calculated as weight in kilograms divided by height in meters squared], 28.4; number of cigarette pack-years, 0; forced expiratory volume in 1 second [FEV1], 97.6% predicted; FEV1: forced vital capacity [FVC] ratio, 0.71; pectoralis muscle area [PMA], 59.4 cm2; pectoralis muscle volume [PMV], 764 cm3) and a male individual with a smoking history and chronic obstructive pulmonary disorder (COPD) (age, 66 years; height, 178 cm; BMI, 27.5; number of cigarette pack-years, 43.2, FEV1, 48% predicted; FEV1:FVC, 0.56; PMA, 35 cm2; PMV, 480.8 cm3) from the Canadian Cohort Obstructive Lung Disease (i.e., CanCOLD) study. The CT image is shown in the axial plane. The PMV is automatically extracted using the developed deep learning model and overlayed onto the lungs for visual clarity.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/03/genkin.25LqljVF0y.jpg?auto=format%2Ccompress&crop=focalpoint&dpr=2&fit=crop&h=167&q=70&w=250)
